Becton, Dickinson and Company (NYSE:BDX - Get Free Report) released its quarterly earnings results on Thursday. The medical instruments supplier reported $3.17 EPS for the quarter, beating analysts' consensus estimates of $2.97 by $0.20, RTT News reports. The business had revenue of $5.05 billion during the quarter, compared to analyst estimates of $5.04 billion. Becton, Dickinson and Company had a return on equity of 13.57% and a net margin of 6.44%. Becton, Dickinson and Company's quarterly revenue was up 4.6% compared to the same quarter last year. During the same quarter in the prior year, the company posted $2.86 EPS. Becton, Dickinson and Company updated its FY24 guidance to $12.95-13.15 EPS.
Becton, Dickinson and Company Stock Up 2.8 %
Shares of Becton, Dickinson and Company stock traded up $6.63 during midday trading on Thursday, hitting $240.35. The company had a trading volume of 3,668,998 shares, compared to its average volume of 1,410,217. The company has a debt-to-equity ratio of 0.56, a quick ratio of 0.64 and a current ratio of 1.08. The stock has a market capitalization of $69.44 billion, a P/E ratio of 56.95, a P/E/G ratio of 1.94 and a beta of 0.45. The company has a 50 day moving average of $238.68 and a 200 day moving average of $240.71. Becton, Dickinson and Company has a 52-week low of $229.40 and a 52-week high of $287.32.
Becton, Dickinson and Company Announces Dividend
The company also recently announced a quarterly dividend, which will be paid on Friday, June 28th. Shareholders of record on Monday, June 10th will be issued a dividend of $0.95 per share. The ex-dividend date of this dividend is Monday, June 10th. This represents a $3.80 dividend on an annualized basis and a dividend yield of 1.58%. Becton, Dickinson and Company's dividend payout ratio (DPR) is 90.05%.
Insider Buying and Selling
In related news, SVP Thomas J. Spoerel sold 282 shares of the company's stock in a transaction that occurred on Thursday, March 14th. The stock was sold at an average price of $238.29, for a total value of $67,197.78. Following the sale, the senior vice president now owns 2,276 shares in the company, valued at approximately $542,348.04. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In related news, SVP Thomas J. Spoerel sold 282 shares of the company's stock in a transaction that occurred on Thursday, March 14th. The stock was sold at an average price of $238.29, for a total value of $67,197.78. Following the sale, the senior vice president now owns 2,276 shares in the company, valued at approximately $542,348.04. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Michael David Garrison sold 1,715 shares of the company's stock in a transaction that occurred on Tuesday, April 30th. The stock was sold at an average price of $232.81, for a total value of $399,269.15. Following the completion of the sale, the executive vice president now owns 5,381 shares in the company, valued at approximately $1,252,750.61. The disclosure for this sale can be found here. 0.31% of the stock is currently owned by company insiders.
Analysts Set New Price Targets
A number of research analysts have commented on BDX shares. Raymond James upped their price target on Becton, Dickinson and Company from $269.00 to $275.00 and gave the company an "outperform" rating in a research report on Wednesday, January 3rd. Barclays upped their target price on Becton, Dickinson and Company from $301.00 to $305.00 and gave the stock an "overweight" rating in a report on Monday, February 5th. Two analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat, Becton, Dickinson and Company currently has a consensus rating of "Moderate Buy" and a consensus target price of $280.00.
Get Our Latest Research Report on BDX
About Becton, Dickinson and Company
(
Get Free Report)
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.
Further Reading
Before you consider Becton, Dickinson and Company, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Becton, Dickinson and Company wasn't on the list.
While Becton, Dickinson and Company currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.
Get This Free Report
